TITLE

Veteran researchers' advice to new researchers

PUB. DATE
April 2008
SOURCE
Clinical Trials Administrator;Apr2008, Vol. 6 Issue 4, p42
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the advice given by Doctor Roy Fleischmann, clinical professor of medicine at the University of Texas Southwestern Medical Center in Dallas, Texas, to new researchers in the clinical trial industry. He states that when he started doing studies, they were designed to ask a question and answer that question. He advises new researchers to be very careful about how they select protocols. He adds that the key to success is to find the right study for the right patient.
ACCESSION #
31620299

 

Related Articles

  • Clinical Trials in New Europe. DOIG, AL // Bio-IT World;Jan2009, Vol. 8 Issue 1, p13 

    The article presents an outlook for clinical trials in New Europe for 2009. The collapse of the Soviet Union is cited as one of the major factors which contributed to the emergence of new opportunity for clinical trials in Europe. An overview of the report from Insight Pharma Reports entitled...

  • Relevance of the clinical impact factor. Blitzkow, Gilson; Estrela, Carlos // Dental Press Endodontics;Jan-Apr2015, Vol. 5 Issue 1, p5 

    The author discusses the importance of systematic literature reviews to analyze clinical impact factors and select accurate and appropriate articles.

  • Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Dinnett, Eleanor M; Mungall, Moira MB; Kent, Jane A; Ronald, Elizabeth S; McIntyre, Karen E; Anderson, Elizabeth; Gaw, Allan // Clinical Trials;2005, Vol. 2 Issue 3, p254 

    Background The gold standard clinical trial design is the double-blind, randomized, controlled trial. No standard practice exists for the "unblinding" of trial participants and no legal obligation is placed on investigators to inform participants of their treatment allocation or study results at...

  • Subjective endpoints in clinical trials: the case for blinded independent central review. Walovitch, Richard; Bin Yao; Chokron, Patrick; Helen Le; Bubley, Glenn // Open Access Journal of Clinical Trials;2013, Vol. 5, p111 

    Primary efficacy and safety endpoints in clinical trials are often subjective assessments made by site personnel. For international confirmatory trials conducted over broad geographic regions and different clinical practice settings, variability in these subjective assessments can be...

  • Sum > parts: Building a high performance CR team.  // Clinical Trials Administrator;Dec2009, Vol. 7 Issue 12, p139 

    The article outlines steps that clinical research (CR) sites can take when developing a high performance clinical trial research team. Emphasis is given on the importance of starting a chartering process which involves understanding the team's purpose as well as the need to keep organization's...

  • Improve your research contract, negotiation skills.  // Clinical Trials Administrator;Mar2010, Vol. 8 Issue 3, p34 

    The article offers helpful information on improving research contracts by understanding the motivations of the parties involved. It advises clinical administrators and investigators to know what benefits can be gained such as the publication rights of the study while the sponsors have different...

  • Oncology Trial Comparator Drug Reimbursement: A Canadian Perspective. Deakin, Denise // Applied Clinical Trials;Apr/May2014, Vol. 23 Issue 4/5, p32 

    The article examines the Canadian comparator reimbursement climate to better inform trial expansion decisions. The author talks about the importance of comparators in cancer trials in the country. Also tackled is the potential for Canada to be a prospective region for the expansion of both early...

  • Europe's restrictive rules strangling clinical research. Bosch, Xavier // Nature Medicine;Dec2005, Vol. 11 Issue 12, p1260 

    The article focuses on the decline of the number of large clinical trials across Europe a year after new rules on clinical research went into effect. The rules, meant to promote Europe-wide research, might instead force scientists to limit their trials to a single country, experts caution. The...

  • REGULACIÓN DE LA INVESTIGACIÓN CLÍNICA Y COMITÉS DE ÉTICA EN PERÚ: CRÓNICA DE CAMBIOS. del Carpio Toia, Agueda Muñoz // Acta Bioéthica;2008, Vol. 14 Issue 2, p193 

    Due to the progressive advance of clinical investigation, new demands and requirements are made necessary, such as: the formation of ethics committees, the creation or adaptation of legislation, and increased training for researchers, among others. The objective of this article is to report on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics